CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share (CTMX) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2015 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.00001 per share
Symbol
CTMX on Nasdaq
Shares outstanding
167,888,095
Price per share
$5.93
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
144,041,189
Total reported value
$613,618,926
% of total 13F portfolios
0%
Share change
+5,763,278
Value change
+$47,271,291
Number of holders
120
Price from insider filings
$5.93
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share (CTMX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +18% $105,171,344 +$17,756,285 24,688,109 +20% FMR LLC 31 Dec 2025
Venrock Healthcare Capital Partners III, L.P. 9.4% +15% $49,641,185 +$8,195,110 15,561,500 +20% Venrock Healthcare Capital Partners III, L.P. 30 Sep 2025
Longitude Capital Partners V, LLC 7.3% $8,192,307 11,538,461 Longitude Capital Partners V, LLC 13 May 2025
PERCEPTIVE ADVISORS LLC 5.9% $22,458,029 9,680,185 Perceptive Advisors LLC 14 Aug 2025
VANGUARD GROUP INC 6% $21,292,132 9,379,794 The Vanguard Group 30 Jun 2025
BIOTECHNOLOGY VALUE FUND L P 3.5% -47% $17,250,001 -$17,250,001 5,769,231 -50% BVF PARTNERS L P/IL 03 Jul 2025
Point72 Asset Management, L.P. 2.5% -52% $12,978,754 -$12,811,193 4,068,575 -50% Point72 Asset Management, L.P. 30 Sep 2025
ORBIMED ADVISORS LLC 2.1% -66% $15,160,295 -$21,224,155 3,525,650 -58% OrbiMed Advisors LLC 31 Dec 2025
Seven Fleet Partners LP 0.2% $267,784 377,161 Seven Fleet Partners LP 13 May 2025
Seven Fleet Capital Management LP 0.02% $155,985 48,898 Seven Fleet Master Fund LP 30 Sep 2025

As of 31 Dec 2025, 120 institutional investors reported holding 144,041,189 shares of CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share (CTMX). This represents 86% of the company’s total 167,888,095 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share (CTMX) together control 77% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 15% 24,688,109 +60% 0.01% $105,171,344
VR ADVISER, LLC 9.3% 15,561,500 0% 3.3% $66,291,990
PERCEPTIVE ADVISORS LLC 5.8% 9,680,185 0% 0.76% $41,237,588
Kynam Capital Management, LP 5.3% 8,966,077 +146% 2.5% $38,195,488
VANGUARD GROUP INC 5% 8,475,584 -5.3% 0% $36,105,988
Commodore Capital LP 4.6% 7,692,300 0% 2.2% $32,769,198
Point72 Asset Management, L.P. 3.1% 5,189,538 +28% 0.03% $22,107,432
STATE STREET CORP 3.1% 5,140,931 +697% 0% $21,900,366
BAKER BROS. ADVISORS LP 2.5% 4,250,826 0% 0.11% $18,108,519
ADAR1 Capital Management, LLC 2.5% 4,182,769 +3.4% 1.3% $17,818,596
Balyasny Asset Management L.P. 2.3% 3,872,202 -1% 0.03% $16,495,581
Financial Engines Advisors L.L.C. 2.3% 3,828,717 +177% 0.03% $16,310,334
BlackRock, Inc. 2.2% 3,669,393 +54% 0% $15,631,615
ORBIMED ADVISORS LLC 2.1% 3,525,650 -58% 0.32% $15,019,269
Ikarian Capital, LLC 1.9% 3,172,616 -5.9% 1.8% $13,515,344
Vivo Capital, LLC 1.7% 2,884,615 0% 0.79% $12,288,460
Eversept Partners, LP 1.5% 2,507,090 0.6% $10,680,203
GOLDMAN SACHS GROUP INC 1.5% 2,460,944 +450% 0% $10,483,622
Woodline Partners LP 1.4% 2,337,005 0% 0.04% $9,955,641
TWO SIGMA INVESTMENTS, LP 0.93% 1,560,755 +114% 0.01% $6,648,816
GEODE CAPITAL MANAGEMENT, LLC 0.91% 1,525,666 -2.8% 0% $6,502,652
DIMENSIONAL FUND ADVISORS LP 0.77% 1,289,656 +186% 0% $5,492,186
MARSHALL WACE, LLP 0.69% 1,156,936 +4.7% 0% $4,928,547
Qube Research & Technologies Ltd 0.63% 1,061,128 +766% 0.01% $4,520,405
STEMPOINT CAPITAL LP 0.62% 1,036,311 0.76% $4,414,685

Institutional Holders of CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share (CTMX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 144,041,189 $613,618,926 +$47,271,291 $4.26 120
2025 Q3 137,411,371 $438,342,190 +$24,527,196 $3.19 102
2025 Q2 133,305,109 $302,602,132 +$213,797,054 $2.27 82
2025 Q1 45,180,958 $28,723,084 -$1,507,772 $0.64 63
2024 Q4 46,714,805 $48,111,898 -$6,381,441 $1.03 68
2024 Q3 51,193,741 $60,427,306 +$480,690 $1.18 69
2024 Q2 50,687,257 $61,863,474 +$334,609 $1.22 73
2024 Q1 44,548,308 $97,118,414 +$26,024,246 $2.18 85
2023 Q4 32,640,376 $50,592,909 +$410,206 $1.55 66
2023 Q3 32,393,313 $41,785,804 -$2,418,556 $1.29 61
2023 Q2 34,120,916 $58,688,106 -$2,378,087 $1.72 66
2023 Q1 35,594,054 $53,751,153 -$933,381 $1.51 74
2022 Q4 35,979,014 $120,192,376 -$724,794 $1.60 77
2022 Q3 36,281,610 $52,604,898 -$18,986,577 $1.45 76
2022 Q2 45,579,430 $83,410,352 -$17,825,825 $1.83 86
2022 Q1 53,661,262 $143,355,949 -$1,754,233 $2.67 112
2021 Q4 54,342,875 $235,299,521 -$5,313,006 $4.33 106
2021 Q3 53,978,233 $274,775,521 -$17,338,127 $5.09 111
2021 Q2 56,688,576 $358,879,555 +$4,313,452 $6.33 119
2021 Q1 54,613,642 $422,156,729 +$130,257,296 $7.73 123
2020 Q4 37,995,365 $248,881,255 +$5,576,359 $6.55 123
2020 Q3 36,841,081 $245,069,950 -$11,639,890 $6.65 128
2020 Q2 37,758,348 $314,514,192 +$15,532,613 $8.33 133
2020 Q1 36,087,916 $276,879,388 +$244,869 $7.67 113
2019 Q4 36,001,618 $299,160,261 -$9,333,104 $8.31 119
2019 Q3 35,837,109 $264,433,175 -$1,377,891 $7.38 111
2019 Q2 35,647,194 $399,598,509 -$8,094,164 $11.22 108
2019 Q1 36,897,584 $396,629,592 -$12,805,896 $10.75 110
2018 Q4 37,768,617 $569,884,178 -$2,745,916 $15.10 108
2018 Q3 37,780,542 $697,391,587 +$95,602,749 $18.50 119
2018 Q2 32,308,752 $738,633,935 +$66,042,910 $22.86 139
2018 Q1 28,622,740 $814,197,912 +$73,379,749 $28.45 136
2017 Q4 30,146,848 $636,945,631 +$56,049,834 $21.11 119
2017 Q3 24,242,512 $440,733,363 +$42,038,227 $18.17 97
2017 Q2 22,105,676 $342,719,825 +$44,092,931 $15.50 89
2017 Q1 19,204,130 $331,600,145 +$58,337,064 $17.27 86
2016 Q4 16,857,707 $185,279,386 +$14,954,410 $10.99 68
2016 Q3 19,725,140 $242,759,481 +$18,076,577 $15.68 61
2016 Q2 18,845,409 $149,178,103 +$16,034,432 $10.21 59
2016 Q1 12,778,869 $164,816,000 +$3,379,204 $12.90 47
2015 Q4 12,469,279 $258,260,359 +$239,918,359 $20.87 47